Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits by Slot Nielsen, Mette et al.
Continuous MPTP intoxication in the Göttingen 
minipig results in chronic parkinsonian deficits
Mette Slot Nielsen1 *, Andreas Nørgaard Glud1,5, Arne Møller2, Poul Mogensen3, Dirk Bender4,  
Jens Christian Sørensen5, Doris Doudet2, and Carsten Reidies Bjarkam1,5
1 Department of Biomedicine, Center for Experimental Neuroscience (CENSE), Aarhus University, Aarhus, Denmark, 2 Center for Functionally 
Integrative Neuroscience (CFIN), Aarhus University Hospital, Aarhus, Denmark, 3 Hammel Neurocenter, Hammel, Denmark, 4 PET Center, 
Aarhus University Hospital, Aarhus, Denmark, 5 Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark,  
* Email: metsloni@rm.dk
Parkinson’s disease (PD) is a common neurodegenerative disorder, resulting from progressive loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc). Neuroprotective therapies in PD are still not available, perhaps because animal models do 
not imitate the chronic and progressive nature of the clinical state of PD. To address this, we performed a feasibility study aimed 
at establishing a chronic non-primate large animal PD model in Göttingen minipigs based on continuous infusion of the neurotoxin 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Twelve female Göttingen minipigs were divided into groups of 2–4 animals and 
implanted with infusion pumps for continuous intramuscular MPTP delivery of 4–24 mg MPTP/day for 11 weeks. The animals showed 
parkinsonian symptoms with bradykinesia, rigidity, coordination and chewing difficulties. Symptoms were stable in the 12 and 18 mg 
MPTP/day groups, whereas the remaining groups showed partial or full behavioral recovery. Digital gait analysis, high performance 
liquid chromatography (HPLC) measurements and stereological counts of tyrosine hydroxylase-positive (TH+) neurons in the SNc 
revealed a dose-related decrease in gait velocity, striatal metabolite levels and neuron numbers with increasing doses of MPTP. No 
neuronal inclusions were observed, but alpha-synuclein staining intensified with increased cumulative MPTP dosages. We conclude 
that this large-animal model of chronic MPTP administration in Göttingen minipigs shows trends of stable parkinsonian deficits 
at 18  mg MPTP/day in all modalities examined. This PD model shares many of the characteristics seen in patients and, although 
preliminary, holds considerable promise for future pre-clinical trials of neuroprotective therapies.
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INTRODUCTION
Parkinson disease (PD) is a progressive 
neurodegenerative disorder resulting from an excessive 
loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNc), leading to a subsequent loss of striatal 
dopamine (DA). Great advances in the treatment of PD 
and the understanding of the biochemical pathology 
of the disease have been achieved using animal models 
exhibiting nigro-striatal damage in a variety of species 
such as rodents and primates (Bergman et al. 1990, 
Carlsson 2002, Jankovic 2006). However, most existing 
animal models of PD exhibit acute neuronal damage and 
not the progressive neuronal loss as seen in PD patients 
and many do not develop the characteristic protein 
aggregates known as Lewy bodies (Braak et al. 2003, 
Jenner 2008, Giráldez-Pérez et al. 2014). The lack of slow 
onset and progressive course of the existing PD models 
may be an important contributing factor to the fact 
that substances displaying promising neuroprotective 
effects in animal studies of PD have failed in human 
clinical trials (Kalia et al. 2015, Suchowersky et al. 2006, 
Yacoubian and Standaert 2009). Therefore, better, more 
representative animal models are needed in order 
to adequately test neuroprotective strategies in PD 
(Carvey et al. 2006, Jenner 2008). Continuous MPTP or 
rotenone infusion in mice or rats seemed promising, 
with animals displaying progressive behavioral changes 
and even alpha‑synuclein (α‑syn) positive neuronal 
inclusion bodies (Betarbet et al. 2000, Fornai et al. 2005). 
Nevertheless, alternatives to rodent models are greatly 
needed to approach neuroprotection research to PD 
patients. In this pursuit we found the Göttingen minipig 
pig advantageous as a non-primate large experimental © 2
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animal. The animal weighs 20–40 kg and its large gyrated 
brain (6×5×4 cm, weight approximately 70 g) has a great 
subcortical anatomical resemblance to primates (Bjarkam 
et al. 2001, Ettrup et al. 2010, Félix et al. 1999, Larsen et 
al. 2004, Nielsen et al. 2009, Rosendal et al. 2009a). PET 
and MRI scanning procedures are possible in the minipig 
brain as well as conventional neurosurgery, stereotaxic 
neurosurgery and surgical implantation of stem cells 
and human-sized devices (Andersen et al. 2005, Bjarkam 
et al. 2001, 2004, 2008a, 2008b, 2009, 2010, Dall et al. 2002, 
Dalmose et al. 2004, 2005, Danielsen et al. 2000, Ettrup et 
al. 2011, 2012, Fjord-Larsen et al. 2010, Glud et al. 2011, 
Jensen et al. 2009, Lind et al. 2007, Norgaard Glud et al. 
2010, Rosendal et al. 2009b, 2010, Sørensen et al. 2000, 
Watanabe et al. 2001). The pig genome resembles that 
of primates (Wernersson et al. 2005), and as opposed 
to primates, pigs are not a biohazard, making handling 
and housing easier and more affordable. Furthermore, 
many of the ethical considerations associated with the 
use primates as experimental animals may be avoided, 
enabling inclusion of more animals in each study and 
thereby potentially obtaining more valid results (Aziz 
2006, Goodman and Check 2002, Dolezalova et al. 2014). 
To address the need of a non-primate large animal 
model for neuroprotective studies in PD we set out to 
develop, thoroughly describe and validate a modified 
model of parkinsonism in the Göttingen minipig based 
on continuous MPTP-infusion. In this feasibility study we 
included few animals in each group for the purpose of 
providing preliminary evidence of optimal MPTP doses and 
methods for evaluating parkinsonian deficits and degrees 
of nigro‑striatal damage. This study represents the first of 
its kind in a large animal and its results are of importance to 
future large-scale validation studies, aimed at developing 
an animal model of PD more closely imitating the clinical 
state and course of PD seen in patients.
MATERIALS AND METHODS
Animals
A total of 16 female Göttingen minipigs (Ellegård 
Göttingen Minipigs A/S, 4261 Dalmose, Denmark) 
approximately 1-year-old were used for this study approved 
by the Danish National Council for Animal Research Ethics 
(DANCARE). Twelve animals were chronically MPTP 
intoxicated as described below, and the remaining 4 were 
kept as normal controls. The animals were kept in pairs 
in a stable with an air temperature of 21 +/−1°C, a relative 
humidity of 50 +/−2% and an air change of 12 times/hour. 
The stable was artificially illuminated with 12 h light and 
12 h darkness. The animals were allowed to acclimate for 
3–4 weeks before the surgical pump implantation.
MPTP stability.
Prior to the experiment the stability of the MPTP HCl 
(M-0896, Sigma-Aldrich, St. Louis, Missouri) was tested 
with high performance liquid chromatography (HPLC), 
confirming its stability at 39°C (the body temperature of 
the minipig) for 5 months. Briefly, HPLC was performed 
employing a reverse-phase column Suplex pKb-100 
(4.6×150 mm, 5 µm; Supelco Inc., Bellefonte, Pennsylvania). 
The mobile phase was a mixture of 25% acetonitrile and 
75% 25 mM potassium phosphate (pH 7.4) at a flow rate of 
1 ml/min and monitoring was performed at 265 nm. See 
Yoshihara and others (2000) for details.
MPTP intoxication
On the day of surgery, the animals were deeply 
anesthetized with a combination of ketamine (125 mg 
im+62.5 mg iv), midazolam (25 mg im+12.5 mg iv) and 
isoflurane (inhalation, 5% for 2 minutes, then reduced to 
1.5%). Under sterile conditions, a Medtronic Syncromed 
II 8637-40 (40 mL) programmable pump (Medtronic, 
Minneapolis, Minnesota) filled with MPTP HCl 10 mg/ml 
was implanted subcutaneously on the right side of the back 
of each pig (Figs 1A and 1B). A Medtronic catheter 8709SC 
was connected to the pump, cut to an appropriate length 
and its tip placed intramuscularly in the back of the animal. 
The skin was sutured tightly in three layers. Antibiotics 
(benzylpenicillin 300,000 IE im) were administered 1 day 
pre-operatively, on the day of the surgery and 5 days 
postoperatively. Analgetics (flunixin 50 mg im) were 
administered 3 days postoperatively. Each pump was 
programmed with an external Medtronic En’Vision unit for 
continuous MPTP delivery. The twelve animals in the MPTP 
group were divided into 5 groups, receiving 4 mg MPTP/day 
(n=2), 6 mg MPTP/day (n=2), 12 mg MPTP/day (n=2), 18 mg 
MPTP/day (n=4) or 24 mg MPTP/day (n=2). When required, 
the pumps were refilled transcutaneously under sterile 
conditions in animals anesthetized with azaperone 
(200 mg) and midazolam (25 mg+25 mg pn) im. The ten pigs 
receiving 4–18 mg MPTP/day had the infusion protocol last 
11 weeks. The two animals receiving 24 mg MPTP/day had 
the infusion stopped after 11 days as the animals expressed 
severe parkinsonian deficits compromising food and water 
intake, and levodopa (L-dopa) (levodopa 50 mg/carbidopa 
12.5 mg p.o., 1–3 times daily) was administered to these 
animals as supportive measures for the remainder of the 
study. These two minipigs were sacrificed at the end of 
the 11 weeks’ protocol i.e. after 11 days of intoxication 
followed by 9 weeks of recovery. Two animals in the 18 mg 
MPTP/day group also received L-dopa substitution therapy 
due to severe parkinsonism, but without cessation of the 
MPTP infusion.
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Two animals developed a skin infection over the 
pump area, and this was managed with antibiotics 
(benzylpenicillin 300,000 IE im) and transcutaneous 
drainage under general anesthesia with azaperone (200 mg) 
and midazolam (25 mg) im. The pumps were not removed 
and the infusions continued throughout the treatment.
The remaining four control animals were anesthetized 
as described above and received a skin incision and were 
sutured in a location similar to the location of the pump 
in the MPTP group. However, due to the high cost of the 
pumps, the control animals did not have pumps implanted.
Behavioral analysis
The pigs were observed for the next 11 weeks at 0, 1 week, 
2, 2.5, 4, 5, 7 and 10–11 weeks. Evaluations were performed 
in the stable with at least 10 minutes of observation by 
authors MSN and AM according to a behavioral score 
scheme modified from Mikkelsen and others (1999) to 
include motility (0–5), coordination (0–5), rigidity (0–2), 
chewing (0–2) and vocalization (0–2), with 0 denoting the 
normal state and 5/2 the most severe expression. Motility 
was evaluated in degree of bradykinesia; coordination in 
crossing of hind or front limbs or both; rigidity by flexion/
extension of the hind limb; chewing by time spent to eat 
chocolate treats; and vocalization by the ability to make 
normal sounds, a pathological high pitch sound or by loss 
of ability to vocalize. A total score of 0 was normal, 1–5 was 
regarded mild, 6–11 moderate and 12–16 indicated severe 
parkinsonism. L-dopa substitution therapy was paused for 
at least 18 hrs prior to behavioral evaluation. 
Gait analysis
Digital gait analysis was modified from previous clinical 
studies (Johnsen et al. 2009, Mogensen and Jakobsen 2001) 
and performed for each pig pre-operatively and after 4 and 
11 weeks of MPTP intoxication. Each pig served as its own 
internal control, comparing its pre- and post-operative 
gait velocities. Prior to the first analysis the animals were 
trained to walk in a flat, fenced area with author MSN using 
chocolate (e.g. M&M’s®) as treats (Fig. 1C). Animals in need 
of L-dopa therapy did not receive the drug for at least 
24 hrs prior to the gait analysis. Six infrared Vicon cameras 
were placed on tripods around the fenced area. Reflective 
ball-shaped markers were placed with double-stick tape 
distally on both hind limbs and the right fore limb, on the 
right thigh and between the highest point of the shoulders. 
The cameras recorded the positions of the markers in space. 
The 2D coordinates from each camera were digitalized and 
transformed to one set of 3D coordinates and from this, gait 
velocity was calculated. 
Euthanasia
At the end of the 11 weeks of infusion or observation, the 
animals were anesthetized with ketamine and midazolam as 
described above and through a burr hole in the skull biopsies 
for HPLC were taken from the left striatum and snap frozen 
in liquid nitrogen. Each animal was then euthanized with 
intracardial pentobarbital injection (2 g) before transcardial 
perfusion with 5 L 4% paraformaldehyde (PFA). The brains 
were removed and the brain stem containing SNc dissected 
according to the method described in Nielsen and others 
(2009). The right striatum was cut coronally and divided in a 
rostral and caudal part. The pumps were removed and their 
function verified.
Histology
The brain stems and right striatae were paraffin 
embedded and serial 30-µm-thick sections mounted on glass 
slides before immunohistochemical staining for tyrosine 
hydroxylase (TH) or α‑syn. Immunohistochemistry was 
Fig. 1. (A) Implantation of pump for continuous MPTP delivery. The pump was placed subcutaneously behind the scapula of the minipig. and a catheter 
connected to the pump placed in the deep muscles of the back for im drug delivery. (B) The 40 ml pump was programmable and refillable transcutaneously. 
(C) For the digital gait analysis, each pig was trained with chocolate treats to walk in a fenced area. Reflective markers were placed on the limbs and between 
the shoulders of the animal, and 6 infrared Vicon cameras registered the location of the markers in space. From this, gait velocity was objectively measured.
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performed directly on the slides as described previously 
(Nielsen et al. 2009), using monoclonal rabbit anti-tyrosine 
hydroxylase (P 40101-0, Pel Freez, Rogers, Arkansas) 
diluted 1:600 or polyclonal sheep anti-alpha-synuclein 
(ab6162, Abcam, Cambridge, UK) diluted 1:100 as primary 
antibodies. Visualization was performed by use of a 
biotinylated secondary antibody (anti-rabbit Ig, Amersham, 
Buckinghamshire, UK diluted 1:200, or anti‑sheep Ig, diluted 
1:400) followed by strepavidin horseradish peroxidase 
(Sigma) and final exposure to diaminobenzidine (DAB). 
α‑syn stained sections were counter‑stained with toluidine 
blue. Omission of both primary antibodies resulted in 
lack of staining. In addition, separate nigral sections were 
stained with hematoxylin-eosin (HE).
Metabolite measurements
To determine the concentration of dopamine (DA), 
3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic 
acid (HVA) and 3-methoxythyramine (3-MT) the left 
striatal samples were thawed and homogenized with a 
Teflon pistil, adding 0.5 ml ice‑cold 0.5 M/l perchloric 
acid containing 0.05% w/v sodium thiosulfate (Pharmacy, 
Aarhus University Hospital, Aarhus, Denmark). The 
homogenate was centrifuged for 5 min at 13000 rpm. The 
supernatant was analyzed by HPLC using Perkin-Elmer 
Series 200 HPLC pump (Titan) connected in series with 
a Rheodyne 7025 injector (80 µl loop), a Phenomenex 
Sphereclone 5µ ODS (2) (250×4.6 mm, Phenomenex, 
Torrance, California), a Dionex PED II electrochemical 
detector in amperometry mode (sensitivity 1 µA). For data 
acquisition Dionex Chromeleon Software 6.8 was used. 
The mobile phase was a mixture of 80% buffer containing 
0.1 M NaH2PO4×H2O (13.8 g/l), 2.6 mM octanesulphonic 
acid sodium salt (0.6 g/l), 0.1mM EDTA (38 mg/l), pH 3.3 
adjusted with acetic acid and 20% methanol. At a flow 
rate of 1 ml/min, DOPAC eluted around 9 min, dopamine 
around 15 min, HVA around 21 min and 3-MT around 
36 min. Further details can be seen in Gamache and others 
(1993) and Mikkelsen and colleagues (1999). Metabolite 
concentrations were determined by comparison to the 
peaks produced by injection of the respective standards 
at the fixed concentration of 2 µg/ml each. 
Fig. 2. Behavioral scores during the observation period. (A) The 4 mg MPTP pigs (n=2) displayed the same mild and remitting scores and are therefore 
depicted in one line. The 6 mg MPTP animals (n=2) showed mild symptoms, also with remission to the normal state. (B) The 12 mg MPTP group (n=2) 
showed mild, if any, parkinsonian symptoms. (C) In the 18 mg MPTP group (n=4) three animals (#9, 11, 12) showed moderate and stable symptoms. Pig 
#10 showed signs of remission following the initial effect. However, parkinsonian symptoms increased towards the end of the observation period in all 
but #12. (D) The 24 mg MPTP animals (n=2) showed severe parkinsonian deficits and had their pumps turned off after 11 days of intoxication (gray vertical 
line). These animals were regarded acutely and not chronically intoxicated, and remitted from severe to moderate PD, remaining stable throughout the 
rest of the observation period.
5_713_Nielsen_v5.indd   202 09/09/16   21:10
Acta Neurobiol Exp 2016, 76: 199–211 Chronic porcine MPTP model 203
Stereology
The total number of TH-positive (TH+) neurons in 
the SNc was estimated on both the right and left sides 
on TH-stained sections according to our previous 
study (Nielsen et al. 2009), utilizing the optical 
fractionator technique (West 1999), using a Zeis 
AxioPlan microscope interfaced with MicroBrightField 
StereoInvestigator software. A 40× air lens was used. 
The final section thickness was measured to 28 µm. 
∑Q¯ represents the total counts from each SNc, and 
the total number of neurons, N, was calculated as 
follows: Every 10th section of the SNc was used, making 
the section sampling fraction, ssf=1/10. The counting 
frame had an area of 7,000 μm², and the area associated 
with each step made by the computer over the section 
surface was 22,500 µm², 90,000 µm² or 160,000 μm², 
depending on the MPTP dose of the animal (the larger 
the dose, the smaller the step due to assumed fewer 
neurons), making the area sampling fraction, asf=0.311, 
asf=0.078, or asf=0.044, respectively. The relation 
between the section thickness (t=28 μm) and the height 
of the optical dissector (h=15 μm), t/h, was 28/15. Thus 
N=∑Q¯×(1/ssf)×(1/asf)×(t/h). 
RESULTS
Behavior
Abnormal behavior was observed in all groups of 
MPTP-intoxicated animals. Initially, the animal would 
lean its thigh against the wall. Then followed lack 
of coordination, primarily of the hind limbs and in 
severe cases the front limbs. General bradykinesia and 
freezing episodes could progress to akinesia in the most 
extreme cases. We also observed prolonged chewing and 
disturbances in normal vocalization (normal sounds 
progressing to abnormal sounds and finally to inability 
to vocalize). Only severely affected animals displayed 
reliably assessable rigidity of the limbs. There was no 
tremor, except in the acute stage of intoxication in 
the 24 mg MPTP animals. For the 4–12 mg MPTP pigs, 
mild symptoms were observed after 10–21 days of 
intoxication, with most of the animals showing partial 
or full behavioral recovery after 7 weeks of intoxication, 
despite the on-going active infusion (Figs 2A and 2B). 
The four 18 mg MPTP animals developed symptoms 
of moderate to severe PD after approximately 2 weeks 
and all but one (pig #10) showed moderate and stable 
Fig. 3. Average behavioral scores compared to the daily MPTP dose and the cumulative MPTP dosage at 4 and 11 weeks of observation. Note the recovery 
of the 6 mg MPTP animals, despite high cumulative dosage compared with the 24 mg animals, where infusion was stopped after just 11 days. Also note 
that the 12 and 18 mg groups as the only groups show stable behavioral scores from the 4- to the 11-week observations (A and C). The numbers 4–24 in 
B and D refer to mg MPTP/day.
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behavioral deficits. In three animals, progressive 
impairments and behavioral scores was seen towards 
the end of the observation period (Fig. 2C). The two 
most severely affected animals in this group received 
L-dopa to ensure proper food intake. The 24 mg MPTP 
animals employed severe parkinsonism after just 
11 days of intoxication. Their pumps were turned off 
to prevent further progression of the symptoms and 
the animals were administered L-dopa therapy. They 
quickly recovered and stabilized into moderate PD 
without any signs of progression (Fig. 2D). Comparing 
the average behavioral scores at 2 and 11 weeks with the 
daily MPTP doses confirmed full recovery in the 4 and 
6 mg groups overall and partial recovery of the 24 mg 
group (Figs 3A and 3C). The 12 and 18 mg groups showed 
stable scores. When comparing the average behavioral 
scores with the total cumulative MPTP dosage, stable 
scores were again seen in the 12 and 18 mg MPTP groups 
from 2 to 11 weeks (Figs 3B and 3D). The 24 mg animals 
demonstrated the classical behavioral feature of acute 
toxicity: initial severe scores with partial recovery 
following interruption of MPTP administration. These 
animals were rated moderately parkinsonian at 11 weeks 
despite the much lower cumulative dose compared with 
the continuously infused animals.
Digital gait analysis
The digital gait analysis pointed to decreased gait 
velocity in the 12 and 18 mg MPTP groups after 4 and 11 
weeks of intoxication (Fig. 4), most distinctly demonstrated 
in the 18 mg MPTP group. Results from a representative 
24 mg animal showed an initial decrease in gait velocity 
at 4 weeks with recovery to normal values at the 11-week 
test, consistent with the observed behavioral recovery. 
The 4–6 mg MPTP animals displayed normal gait velocity 
throughout the observation period and are not shown in 
Fig. 4. We did not observe any effect of training, learning 
or exercise i.e. normal animals did not increase or decrease 
their gait velocity significantly during the course of the 
observation period. 
HPLC
HPLC analysis of striatal DA and its metabolites at the 
end of the 11-week study presented in Figs 5A–5D suggested 
decreased concentrations of DA and its metabolites in 
response to exposure to increasing doses of MPTP, with 
occasional outliers. The relative increase in metabolites in 
the 4 animals receiving 18 mg MPTP/day in comparison with 
the further decrease in DA at that dose suggested an increase 
in turnover. This is supported by Fig. 5E graph in which 
a routinely used index of DA turnover, DA metabolites/DA, 
suggested an increase in the 18 mg daily dose animals as well 
as the animals with the acute moderate to severe lesion.
Histopathology
A trend of dose-dependent neuron loss in the SNc was 
demonstrated on TH-stained sections (Figs 6A–6D). The 
neuron loss was most prominent in the rostral and lateral 
2/3 of the SNc in the lower daily dose groups, but the 18 and 
24 mg MPTP animals displayed a neuronal loss in all parts 
of the SNc. Surviving neurons appeared smaller and more 
heavily stained than in normal animals. In the striatum, the 
12 and 18 mg animals showed swollen TH+ terminals with 
fewer fibers and terminals in the 18 mg group (Figs 6F–6G). 
Some sense of direction of the fibers remained in the 18 mg 
animals, but was lost in the 24 mg animals, which also 
displayed smaller, fewer terminals (Fig. 6H). These changes 
were most prominent in the rostral part of the striatum 
corresponding to the rostral nigral projection. 
The SNc and striatae of MPTP intoxicated animals 
stained positive for α‑syn (Fig. 7). α‑syn was mostly 
visible in the neuropil, but occasional neuronal staining 
Fig. 4. Mean gait velocity during the 11-week observation period in the 
12, 18 and 24 mg MPTP groups. The 4–6 mg animals showed normal gait 
velocities throughout the study. Each animal served as its own normal 
control due to inter-individual variability of normal gait velocity. The pre-
operative gait velocity was set at 100% and changes are depicted in percent 
points. The 12 mg MPTP group, comprising two animals, showed decreased 
gait velocity throughout the observation period. The 18 mg MPTP animals, 
comprising four animals, showed stable and decreased gait velocity at both 
4 and 11 weeks of intoxication. The 24 mg MPTP group is presented here 
with one representative animal, showed decreased gait velocity at 4 weeks 
and increased velocity at 11 weeks. The MPTP intoxication of this group was 
stopped after 11 days and corresponded to acute intoxication.
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in the SNc was also observed, primarily confined to the 
cytoplasm and the cell membrane (Fig. 7B). There were 
no neuronal inclusions. α‑syn stained most intense in 12 
and 18 mg animals receiving continuous MPTP infusion 
compared with the acutely intoxicated 24 mg animals. 
This finding was most prominent in the striatum (Figs 
7E and 7F). Control animals were devoid of specific 
α‑syn reactivity. 
Stereology
The stereological cell counts also suggested a dose-
dependant loss of TH+ neurons (Fig. 6 graph). For reference, 
normal Göttingen minipigs have an estimated 80,700 
neurons in their SNc unilaterally (Nielsen et al. 2009) and 
this number including SD’s was included in Fig. 6. The 
TH and the HE stainings were compared, and the specific 
Fig. 5. HPLC for DA, DOPAC, 3-MT and HVA in the different MPTP groups and normal animals. The number of observations was limited (1 in the 6 and 24 mg 
MPTP groups; 2 in the 0, 4 and 12 mg MPTP groups; and 4 in the 18 mg MPTP group). However, the overall trend was that of a dose-dependent decrease 
in dopamine and related metabolites. The (DOPAC+HVA+3-MT)/Dopamine ratio shown in E is a sensitive marker of dopamine turnover, increasing in the 
18 and 24 mg groups.
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dopaminergic neuronal loss seen on the TH stained sections 
corresponded well with the neuronal loss observed in the 
HE stained sections (data not shown).
DISCUSSION
For the first time, this study suggests that continuous 
im delivery of MPTP for 11 weeks results in chronic and 
stable PD deficits in the Göttingen minipig. We found 
18 mg MPTP/day to be the optimal dose, as the animals 
in this group displayed moderate to severe and stable 
parkinsonian behavior, evidence of decreased gait velocity, 
loss of TH+ neurons evaluated histopathologically and 
stereologically, and a HPLC‑verified decrease in striatal 
dopamine and metabolites. As this was the first study of 
its kind in a large animal, we included just 2 animals in 
each group to target the optimal MPTP dose and doubled 
the number of animals to 4 once this dose was established. 
The small n precluded detailed statistical analysis, but 
provided valuable information for future studies of its kind 
in animals of this size and weight.
The past 10 years’ of research aimed at making the 
pig an attractive animal model for neuroscience research 
has led to detailed descriptions of this animal’s genome, 
subcortical anatomy, neurosurgical, PET and MRI 
scanning procedures and actual disease modeling such 
as PD, Alzheimer’s disease, Huntington’s disease, and 
autonomic and micturiction disturbances (Andersen et 
al. 2005, Baxa et al. 2013, Bjarkam et al. 2001, 2004, 2008a, 
2008b, 2009, 2010, Dall et al. 2002, Dalmose et al. 2004, 
2005, Danielsen et al. 2000, Ettrup et al. 2010, 2011, 2012, 
Félix et al. 1999, Fjord-Larsen et al. 2010, Glud et al. 2011, 
Jensen et al. 2009, Kragh et al. 2009, Larsen et al. 2004, 
Lind et al. 2007, Lindvall and Wahlberg 2008, Mikkelsen 
et al. 1999, Nielsen et al. 2009, Norgaard Glud et al. 2010, 
Ostergaard et al. 1992, Rosendal et al. 2009a, 2009b, 2010, 
Sørensen et al. 2000, Watanabe et al. 2001, Wernersson 
et al. 2005). These studies showed that the pig has 
commonalities with non-human primates and humans 
and may serve as a large animal model, filling the gap 
between neuroscience on rodents and clinical trials on 
patients, as use of non-human primates is becoming 
more difficult. 
Fig. 6. (A–D) TH-staining of the SNc in A – normal; B – 12 mg; C – 18 mg; 
and D – 24 mg MPTP animals at corresponding levels. A dose-dependent 
decrease in the number of TH+ neurons was visible. Scale bar: 1 mm. 
(E–H) TH-staining in the striatum in E – normal; F – 12 mg; G – 18 mg; 
and H – 24 mg MPTP animals. TH+ terminals were swollen in the 12 mg 
animals. Likewise, the 18 mg animals showed swollen terminals, reduced 
in number and with fewer fibers. The 24 mg animals displayed only few 
terminals and fibers, and the fibers appeared completely disorganized. 
Terminals were not as swollen as in the 12 and 18 mg groups. Scale bar: 
20 µm. Graph: the stereological results. n=4 in the 18 mg group, n=2 in 
all other groups. Both SNc’s in each animal were counted. The results 
show the average number of neurons unilaterally. The dose-dependent 
decrease in TH+ neurons seen in Figs 6B–6D was confirmed, pointing 
towards fewer neurons in the 12, 18 and 24 mg MPTP groups. The 
dashed horizontal lines indicate the mean and SD’s in normal Göttingen 
minipigs based on Nielsen and others (2009).
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The MPTP model of selective DA neuron damage 
has been used to investigate the pathogenesis in PD, 
the pharmacological consequences of the DA loss, the 
compensatory adaptations, efficacy testing of new 
symptomatic treatments and the potential of gene 
therapies and alternate neuroprotective approaches. 
Promising results of neuroprotection in rodent and 
primate models with a variety of agents have failed to show 
convincing effects in subsequent clinical trials. A plausible 
explanation could be the lack of current animal models 
for preclinical screening to accurately mimic the slow 
progressive course of the idiopathic disease (Kieburtz and 
Ravina 2007, Olanow et al. 2008). Conventionally, acute 
nigral DA neuron loss has been performed by injecting 
high MPTP doses hours or days apart but usually within 
a short time frame, until the animal displayed persistent 
PD symptoms (Emborg 2004, Przedborski et al. 2001). 
Attempts to mimic progressive neuron loss by subacute/
chronic MPTP intoxication using lower doses over longer 
periods of time have been performed (Bezard et al. 1997, 
Gibrat et al. 2009, Meredith et al. 2008). However, it has 
been argued that this also in essence represents acute 
intoxication (Jenner 2008). Continuous administration of 
MPTP exposes the SNc neurons to chronic toxic stress and 
therefore supposedly models the progressive pathology 
seen in PD patients. This was performed in mice by osmotic 
minipumps (Fornai et al. 2005, Gibrat et al. 2009) and may 
be the closest yet to a true chronic PD toxin model. To date, 
we have not found evidence of continuous administration 
of MPTP or other PD-related neurotoxins in a large animal 
model as performed here. Additionally, our study is the first 
to administer MPTP continuously for as long as 11 weeks. 
The behavioral analysis performed in the minipig 
resembles those described for primates with obvious 
exceptions such as evaluation of facial expression, fine 
hand movements etc. (Bezard et al. 1997, Doudet et al. 
2004, Emborg 2004). Behavioral evaluation in an animal 
model of neuroprotection is very important, and require 
a standardized scoring system, which would optimally 
correspond to the Unified Parkinson Disease Rating Scale 
(UPDRS) assessment in PD patients, as this scale is often 
used in clinical trials for evaluation of treatment efficacy. 
Although blind assessment would be preferred, it was 
impossible in this feasibility study due to the obvious 
presence of the large implanted pumps. Nevertheless, the 
subjective behavioral assessment by two investigators with 
experience in pig behavior was remarkably similar to the 
data obtained from the objective gait analysis, measuring 
movement velocity (see below).
Continuous delivery of 18 mg MPTP/day led to stable 
PD symptoms in 3 out of 4 animals (Fig. 2C). Comparison 
of the average motor scores and daily or cumulative MPTP 
doses suggested stability of the behavioral scores in the 12 
and 18 mg MPTP/day groups (Fig. 3). These observations 
also suggested that the 24 mg animals could be regarded 
as acutely and not chronically intoxicated, as severe 
symptoms occurred quickly and persisted after slight 
recovery despite cessation of the MPTP infusion. This 
behavioral time course was similar to that of acute MPTP 
intoxication described previously in pigs and non-human 
primates (Emborg 2007, Mikkelsen et al. 1999). Clinical 
recovery after acute exposure to MPTP intoxication is 
thorougly described in the literature (Boulet et al. 2008, 
Mikkelsen et al. 1999, Mounayar et al. 2007) in both 
bilaterally and unilaterally lesioned animals. Additionally, 
examination of the animals’ individual clinical responses 
shown in Fig. 2 clearly demonstrated significant variability 
in the sensitivity of the different animals exposed to 
the same dose of MPTP. Similar variability is commonly 
described with toxin exposure in primates, minipigs and 
MPTP-exposed addicts (Ballard et al. 1985, Emborg 2007, 
Mikkelsen et al. 1999). 
As described previously by our group (Glud et al. 2011), 
we confirmed that digital gait analysis is possible on 
properly trained minipigs and offers a sensitive method of 
motor performance assessment. The trends of decreased 
Fig. 7. (A–B) α-syn staining of the SNc in A – control animal and B – 
18 mg animal. Staining was ubiquitous with a predilection to fibers and 
membranes. No neuronal inclusions were observed. Arrow: staining of 
neuronal membrane. (C–F) α-syn staining in the striatum in C – control 
animal, D – 24 mg, E – 12 mg and F – 18 mg animal, showing increased 
staining intensity in the two chronically intoxicated animals (E and F), 
compared with the acutely intoxicated 24 mg animals and intensified 
staining in the 18 mg animal compared with the 12 mg animal. Scale 
bar: 20 µm.
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gait velocity in the 18 mg MPTP group confirmed that 
this was the optimal dose for animals of this age and 
weight. The decreasing trend of the gait velocity from 4 to 
11 weeks in the 12 and 18 mg groups corresponded with the 
behavioral signs of stability to possibly slight progression, 
which however the subjective behavioral analysis was 
not sensitive enough to register. In addition, digital gait 
analysis confirmed the behavioral recovery observed in the 
24 mg group. The gait analysis equipment was previously 
used to assess gait parameters in PD patients (Johnsen et al. 
2009), emphasizing that the pig may help bridge laboratory 
and clinical neuroscience. The minipigs were easily trained 
for the procedure. However, training must be started 
well before the first data analysis acquisition (baseline) 
to avoid the effects of learning and habituation (i.e. the 
animals walking faster and more confidently following the 
investigator) during the actual experimental part of the 
study. Such effects could otherwise easily confound the 
velocity measurements in the preclinical or early phase of 
the intoxication. Decreases in gait velocity after MPTP can 
be reliably measured and used as an objective estimate of 
motor disability. Due to inter-individual variations in the 
normal gait velocity among animals, although the set-up is 
time consuming, it is necessary to obtain sufficient baseline, 
pre-MPTP gait velocity measurements for each individual 
animal for post-operative gait velocity data comparison, 
instead of using a population average gait velocity.
The histopathology suggested a dose-dependent loss 
of TH+ neurons in the SNc, confirmed by stereological cell 
counting. The number of neurons on HE stains correlated 
well with the TH stains, confirming that neurons were 
permanently lost and not just devoid of TH (data not 
shown). This was also reported previously in acute MPTP 
intoxication (Seniuk et al. 1990). The 12 mg MPTP group, 
which showed mild and stable PD symptoms and slightly 
decreased gait velocity, displayed a neuron loss in the 
SNc of about 37%. This observation was consistent with 
previous reports in animal models and in PD patients 
suggesting the existence of a significant amount of internal 
compensation early in the disease: indeed, it is widely 
accepted that at least 50% DA neuronal loss in the SNc is 
necessary for clearly recognizable clinical symptoms. The 
18 mg MPTP group showed greater DA neuron loss (about 
60%), accompanied with significantly more severe motor 
symptoms and decreased DA and metabolites. Interestingly, 
Fig. 5E showed an increased metabolite/DA ratio in this 
group, suggesting increased DA turnover. Increased DA 
turnover has been reported both postmortem and in vivo 
by PET in non-human primates (Doudet et al. 1998) as well 
as in early PD patients (Sossi et al. 2002) and is believed 
to represent one of the early compensatory mechanisms 
to neuronal loss. Our 4–12 mg animals showed variable 
loss of DA and metabolites, relatively stable turnovers 
but little significant motor impairments or decreases 
in TH+ neurons, confirming the very early existence of 
internal compensatory biochemical changes. The 24 mg 
group, however, also showed increased DA turnover, 
similarly consistent with the behavioral and pathological 
observations of serious motor impairments and 78% loss of 
TH+ neurons in the SNc.
The striatal TH staining showed pronounced loss of TH+ 
fibers rostrally, loss becoming more severe and eventually 
more widespread with increasing dose and exposure to the 
toxin. In PD, the dorsolateral striatal quadrant is typically 
the most affected (Bové et al. 2005). This observation 
supports the validity of the proposed model of continuous 
infusion. We did not see evidence of sprouting in any of the 
infused animals as has otherwise been reported previously 
(Song and Haber 2000). 
In contrast to Fornai and others (2005) and Gibrat 
and colleagues (2009) we did not detect α‑syn positive 
intraneuronal inclusions, which is in accordance with others 
studies in chronic MPTP models and monkeys examined 
after 10 years of parkinsonism (Alvarez-Fischer et al. 2008, 
Halliday et al. 2009, Shimoji et al. 2005). However, the 
neuronal inclusions described by Fornai and Gibrat were 
restricted the mice receiving the highest daily doses. It is 
likely that the doses used in our study were not sufficient to 
produce similar effect. We did, however, observe a tendency 
to a more intense α‑syn stain with increased continued MPTP 
doses in contrast to the acutely intoxicated 24 mg animals. 
This could suggest different pathological mechanisms of 
the two different administration regimens. Thus, it has 
been previously shown that acute MPTP intoxication causes 
necrotic cell death whereas chronic intoxication causes 
apoptotic neuron loss (Schmidt and Ferger 2001). Double 
staining of TH and α‑syn to confirm the α‑syn pathology in 
dopaminergic neurons under chronic toxic stress as seen in 
mice is worth performing in future studies in the minipig 
(Gibrat et al. 2009)
The continuous MPTP intoxication used in this study 
required large amounts of toxin. Each 18 mg animal 
received approximately 1200 mg MPTP to produce 
moderate and stable PD. In comparison, the 24 mg acutely 
intoxicated animals received 264 mg MPTP, whereas the 
acutely intoxicated minipigs described by Mikkelsen and 
others (1999) just received approximately 120 mg. Thus 
the chronic administration of MPTP appeared to induce 
a substantial tolerance to the toxin, perhaps as a result 
of hepatic detoxification (Markey and Schmuff 1986, 
Yoshihara et al. 2000). Chronic MPTP intoxication seemed 
to require 10 times as much MPTP as acute intoxication, 
which may raise economical issues. However, if further 
studies of this administration route confirm greater 
similarities to the clinical state of PD than the acute model 
or even show progression when carried out for longer than 
11 weeks, the possibility of valid translational results may 
by far exceed the economical drawback of the model.
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CONCLUSION
The Göttingen minipig model of the chronic PD based 
on continuous MPTP infusion presented here has been 
preliminarily characterized behaviorally, chemically, 
histopathologically and stereologically. Although based 
on few animals, this model already suggests many 
resemblances to the clinical state of PD and provides hope 
for future demonstration of actual disease progression. 
The continued lack of accordance between preclinical 
data of neuroprotective agents and clinical efficacy in 
PD patients keep emphasizing the need for improved PD 
animal models. The pig with its large gyrated brain, low 
cost and easy handling compared with primates along 
with its genetic and subcortical anatomical resemblance 
to primates and possibilities of implantation of stem cells, 
human‑sized devices and gene transfer offers a valuable 
platform for preclinical efficacy and safety experiments. 
We thus propose that this Göttingen minipig model of PD 
based on continuous MPTP intoxication may prove valuable 
in future preclinical neuroprotective studies in PD.
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